Hightower Advisors Has Decreased Its Nektar Therapeutics (NKTR) Stake by $476,720; Stock Value Rose; Fuller & Thaler Asset Management Has Trimmed Its Pixelworks (PXLW) Stake by $754,080

May 18, 2018 - By Michael Collier

Nektar Therapeutics (NASDAQ:NKTR) Logo

Hightower Advisors Llc decreased its stake in Nektar Therapeutics (NKTR) by 22.4% based on its latest 2017Q4 regulatory filing with the SEC. Hightower Advisors Llc sold 8,080 shares as the company’s stock rose 80.22% while stock markets declined. The institutional investor held 27,985 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.67M, down from 36,065 at the end of the previous reported quarter. Hightower Advisors Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $13.58B market cap company. The stock decreased 7.66% or $6.57 during the last trading session, reaching $79.23. About 5.31 million shares traded or 80.23% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since May 18, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Fuller & Thaler Asset Management Inc decreased its stake in Pixelworks Inc (PXLW) by 24.06% based on its latest 2017Q4 regulatory filing with the SEC. Fuller & Thaler Asset Management Inc sold 125,680 shares as the company’s stock declined 39.22% with the market. The institutional investor held 396,700 shares of the technology company at the end of 2017Q4, valued at $2.51M, down from 522,380 at the end of the previous reported quarter. Fuller & Thaler Asset Management Inc who had been investing in Pixelworks Inc for a number of months, seems to be less bullish one the $144.11M market cap company. The stock decreased 1.46% or $0.06 during the last trading session, reaching $4.05. About 187,834 shares traded. Pixelworks, Inc. (NASDAQ:PXLW) has declined 14.41% since May 18, 2017 and is downtrending. It has underperformed by 25.96% the S&P500.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Benzinga.com which released: “48 Biggest Movers From Yesterday” on May 18, 2018, also Fool.com with their article: “Here’s Why Nektar Therapeutics Fell as Much as 11.1% Today” published on May 17, 2018, Seekingalpha.com published: “Nektar’s (NKTR) CEO Howard Robin on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Seekingalpha.com and their article: “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise” published on May 16, 2018 as well as Nasdaq.com‘s news article titled: “3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies …” with publication date: May 11, 2018.

Investors sentiment decreased to 1.19 in Q4 2017. Its down 0.21, from 1.4 in 2017Q3. It is negative, as 18 investors sold NKTR shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Citigroup Incorporated invested 0% in Nektar Therapeutics (NASDAQ:NKTR). 5,327 were accumulated by Redmile Grp Limited Com. Public Employees Retirement Association Of Colorado stated it has 381,590 shares or 0.15% of all its holdings. Smithfield stated it has 125 shares. State Of Alaska Department Of Revenue reported 31,375 shares stake. Vident Inv Advisory Ltd Liability Com holds 0.07% or 21,339 shares in its portfolio. Qs Limited Liability Company reported 3,612 shares. Assetmark Inc reported 51 shares. Granahan Invest Mngmt Ma has invested 0.74% in Nektar Therapeutics (NASDAQ:NKTR). The North Carolina-based Financial Bank Of America De has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Advisory Rech reported 36,507 shares stake. Tiaa Cref Investment Management Limited Liability stated it has 625,499 shares. Kazazian Asset Ltd Limited Liability Company owns 19,512 shares. Hanson Mcclain has 0% invested in Nektar Therapeutics (NASDAQ:NKTR). State Common Retirement Fund holds 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 169,785 shares.

Hightower Advisors Llc, which manages about $15.08 billion and $12.18B US Long portfolio, upped its stake in Fidelity Comwlth Tr (ONEQ) by 5,012 shares to 22,045 shares, valued at $5.98 million in 2017Q4, according to the filing. It also increased its holding in Spdr Series Trust (XBI) by 186,151 shares in the quarter, for a total of 189,151 shares, and has risen its stake in Laboratory Corp Amer Hldgs (NYSE:LH).

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $0.27 EPS, up 169.23% or $0.66 from last year’s $-0.39 per share. NKTR’s profit will be $46.28M for 73.36 P/E if the $0.27 EPS becomes a reality. After $-0.60 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -145.00% EPS growth.

Since December 13, 2017, it had 0 insider purchases, and 21 insider sales for $88.95 million activity. Nicholson John sold 220,144 shares worth $21.85M. Labrucherie Gil M also sold $288,382 worth of Nektar Therapeutics (NASDAQ:NKTR) shares. $4.64M worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by ROBIN HOWARD W. 502 shares were sold by Hora Maninder, worth $53,046 on Tuesday, April 10. 160,000 shares valued at $14.89M were sold by Doberstein Stephen K on Friday, April 6. Thomsen Jillian B. had sold 13,881 shares worth $1.41 million.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $16 lowest target. $79.50’s average target is 0.34% above currents $79.23 stock price. Nektar Therapeutics had 28 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Canaccord Genuity on Thursday, November 9. The stock has “Buy” rating by Roth Capital on Monday, November 13. As per Wednesday, August 9, the company rating was maintained by Roth Capital. H.C. Wainwright reinitiated the stock with “Buy” rating in Monday, April 2 report. The firm has “Buy” rating given on Wednesday, January 10 by Canaccord Genuity. The firm has “Buy” rating given on Wednesday, August 16 by Jefferies. The company was maintained on Friday, May 11 by Canaccord Genuity. The stock has “Buy” rating by Mizuho on Friday, April 6. The stock has “Overweight” rating by Piper Jaffray on Thursday, January 7. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) on Thursday, July 20 with “Buy” rating.

Investors sentiment decreased to 1.47 in 2017 Q4. Its down 1.03, from 2.5 in 2017Q3. It is negative, as 9 investors sold PXLW shares while 25 reduced holdings. 21 funds opened positions while 29 raised stakes. 12.74 million shares or 5.71% more from 12.05 million shares in 2017Q3 were reported. Natl Bank Of New York Mellon accumulated 92,240 shares. Haverford Tru reported 0% in Pixelworks, Inc. (NASDAQ:PXLW). Credit Suisse Ag invested in 0% or 11,196 shares. Strs Ohio holds 16,700 shares or 0% of its portfolio. State Street invested 0% in Pixelworks, Inc. (NASDAQ:PXLW). Millennium Management Limited Liability holds 0% or 325,095 shares in its portfolio. Manufacturers Life Insurance Commerce The holds 23,226 shares. Emerald Advisers Pa invested in 0.01% or 32,885 shares. Goldman Sachs Grp Incorporated Inc invested 0% in Pixelworks, Inc. (NASDAQ:PXLW). Deutsche Bank & Trust Ag holds 75,071 shares. Jpmorgan Chase holds 0% or 6,154 shares. 180 were reported by Toth Advisory Corporation. Tiaa Cref Ltd reported 73,864 shares or 0% of all its holdings. Macquarie Gru Ltd, a Australia-based fund reported 48,500 shares. Eam Ltd Company reported 99,537 shares.

Fuller & Thaler Asset Management Inc, which manages about $2.14 billion and $8.31B US Long portfolio, upped its stake in Sp Plus Corp (NASDAQ:SP) by 134,640 shares to 229,540 shares, valued at $8.52M in 2017Q4, according to the filing. It also increased its holding in Brixmor Property Group Inc (NYSE:BRX) by 2.89 million shares in the quarter, for a total of 2.90 million shares, and has risen its stake in Priceline Group Inc/The (NASDAQ:PCLN).

Analysts await Pixelworks, Inc. (NASDAQ:PXLW) to report earnings on August, 14. They expect $-0.05 earnings per share, down 171.43% or $0.12 from last year’s $0.07 per share. After $-0.03 actual earnings per share reported by Pixelworks, Inc. for the previous quarter, Wall Street now forecasts 66.67% negative EPS growth.

Since January 31, 2018, it had 3 insider purchases, and 1 insider sale for $166,696 activity. MOORE STEVEN L bought $5,202 worth of stock or 3,000 shares. Shares for $10,450 were sold by Tupman David J.. The insider HENEGHAN DANIEL bought $86,600.

Pixelworks, Inc. (NASDAQ:PXLW) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.